

Mar Cuadrado-Tejedor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9221473/mar-cuadrado-tejedor-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

2,036
citations

23
h-index

40
g-index

40
ext. papers

2,301
ext. citations

5.5
avg, IF

4.51
L-index

#	Paper	IF	Citations
40	Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
39	Identifying the Main Functional Pathways Associated with Cognitive Resilience to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
38	PLA2G4E, a candidate gene for resilience in Alzheimer's disease and a new target for dementia treatment. <i>Progress in Neurobiology</i> , 2020 , 191, 101818	10.9	9
37	Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease 2020 , 213-226		
36	GLUT12 Expression in Brain of Mouse Models of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020 , 57, 798-805	6.2	8
35	Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 4076-4101	5.7	18
34	Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 16, 26-37	10.7	43
33	Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 149	5.3	21
32	Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 1765-1782	5.7	18
31	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. <i>Neurotherapeutics</i> , 2018 , 15, 742-750	6.4	5
30	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018 , 150, 506-524	6.8	35
29	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. <i>Frontiers in Immunology</i> , 2018 , 9, 68	8.4	11
28	Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 638-661	5.7	26
27	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. <i>Neuropsychopharmacology</i> , 2017 , 42, 524-539	8.7	65
26	Chronic Mild Stress Assay Leading to Early Onset and Propagation of Alzheimer's Disease Phenotype in Mouse Models. <i>Methods in Molecular Biology</i> , 2016 , 1303, 241-6	1.4	10
25	Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in Alzheimer Disease Mouse Models. <i>Methods in Molecular Biology</i> , 2016 , 1303, 117-23	1.4	5
24	Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. <i>Journal of Neurochemistry</i> , 2016 , 136, 403-15	6	31

23	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 8967-9004	8.3	59
22	Decreased levels of guanosine 3',5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2015 , 41, 471-82	5.2	65
21	Phosphodiesterase inhibition in cognitive decline. <i>Journal of Alzheimer's Disease</i> , 2014 , 42 Suppl 4, S561-73	4.3	21
20	Synthesis and evaluation of (13)N-labelled azo compounds for amyloid imaging in mice. <i>Molecular Imaging and Biology</i> , 2014 , 16, 538-49	3.8	14
19	Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. <i>EMBO Molecular Medicine</i> , 2014 , 6, 1246-62	12	84
18	Current animal models of Alzheimer's disease: challenges in translational research. <i>Frontiers in Neurology</i> , 2014 , 5, 182	4.1	20
17	Epigenetic drugs in Alzheimer's disease. <i>Biomolecular Concepts</i> , 2013 , 4, 433-45	3.7	26
16	Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. <i>Neuropharmacology</i> , 2013 , 64, 114-23	5.5	109
15	Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer's disease-like phenotype of a commonly used mouse model. <i>Current Pharmaceutical Design</i> , 2013 , 19, 5076-84	3.3	42
14	Age-related mitochondrial alterations without neuronal loss in the hippocampus of a transgenic model of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2013 , 10, 390-405	3	25
13	Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. <i>Hippocampus</i> , 2012 , 22, 1040-50	3.5	173
12	Phosphodiesterases as therapeutic targets for Alzheimer's disease. <i>ACS Chemical Neuroscience</i> , 2012 , 3, 832-44	5.7	180
11	Synthesis of 13N-labelled radiotracers by using microfluidic technology. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012 , 55, 332-338	1.9	20
10	Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 567-78	4.3	44
9	Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation. <i>Behavioural Brain Research</i> , 2011 , 220, 338-43	3.4	34
8	Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Aβeta. <i>Frontiers in Bioscience - Elite</i> , 2011 , 3, 1375-84	1.6	23
7	Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid-β. <i>Journal of Alzheimer's Disease</i> , 2011 , 23, 195-206	4.3	76
6	Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. <i>Neuropsychopharmacology</i> , 2010 , 35, 1593-604	8.7	167

5	Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. <i>Neurobiology of Disease</i> , 2010 , 38, 237-45	7.5	60
4	Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. <i>Neurobiology of Disease</i> , 2009 , 33, 369-78	7.5	83
3	Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. <i>Neuropsychopharmacology</i> , 2009 , 34, 1721-32	8.7	304
2	Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 17, 773-86	4.3	90
1	Changes in cytoskeletal gene expression linked to MPTP-treatment in Mice. <i>Neurobiology of Disease</i> , 2005 , 20, 666-72	7.5	8